Kinetex Polar C18 Core Shell Columns Deliver High Retention and Aqueous Stability

Torrance, CA (May 12, 2017) – Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces the Kinetex 2.6 µm Polar C18 – the ninth selectivity in the Kinetex core-shell family. This stationary phase combines C18 ligands with a polar-modified surface to enable superior retention of polar and nonpolar compounds while ensuring 100 percent aqueous stability.

Incorporating the key performance benefits of the Kinetex Core-Shell Technology, the 2.6 µm Polar C18 particle size provides high efficiency and performance on HPLC systems and potential increases in resolution, sensitivity and separation speed. On UHPLC systems, the 2.6 µm size provides comparable performance to fully porous sub-2 µm particles, but at much lower backpressure levels.

With this new Kinetex particle, Phenomenex now offers the dual polar/nonpolar selectivity of the Polar C18 stationary phase in two particle types – Kinetex core-shell and Luna Omega thermally modified fully porous. This enables researchers to move back and forth between two different solid supports to better address method development needs and wants.

"We are pleased to extend the performance and sensitivity of our Kinetex Core-Shell Technology products to the challenges of retaining and analyzing polar compounds," comments Simon Lomas, strategic marketing manager for Phenomenex." This new selectivity greatly enhances polar/nonpolar retention compared to traditional alkyl phases and gives customers a versatile product with which they can start reversed phase method development."

The new Kinetex Polar C18 is an ideal all-purpose phase for use with mixtures of multiple polar and nonpolar compounds or single-class methods with closely related compounds, such as impurities or metabolites. Key applications that can greatly benefit from this dual selectivity include pesticide screening in food, testing of emerging environmental contaminants and drug analysis in pharmaceutical discovery, toxicology testing and clinical research. For more information, visit

For more information regarding this article please contact:
Phenomenex Press Room
Tel: (310) 212-0555 (USA)